News

    On September 27, 2017 the Supervisory Board of STADA Arzneimittel AG appointed Dr. Claudio Albrecht as new Chairman of the Executive Board with immediate effect. Dr. Albrecht succeeds Engelbert Coster Tjeenk Willink who had held the office of Chairman of...

    Funds advised by Bain Capital Private Equity, LP (“Bain Capital”) and by Cinven Partners LLP (“Cinven”), announced the intention to launch a voluntary public takeover offer (the “Takeover Offer”) for all outstanding shares of STADA Arzneimittel AG...

   We are delighted to announce that Sean Bowler joins APP as Partner. Sean is an engineer who has been Head of Global Engineering and HSE in several major pharmaceutical companies. He has successfully developed and managed corporate systems in areas such as...

   Ino Holdco S.A.R.L appointed Claudio Albrecht as non-executive Director. Ino Holdco is an entity controlled by APAX Partners and is the holding company of Neuraxpharm, Germany and Invent Farma, Spain. APP was already advising APAX during the due diligence...

   APP was appointed to act as an industry advisor to a leading PE house for the acquisition of a mid sized boutique generic company. The company acquired is a player in the field of Active Pharmaceutical ingredients, runs a business to business franchise...

   APP was appointed by a leading Middle East pharmaceutical company to advise them on creating an Oncology business in Iran. The project included product selection, development of a business plan, partner search, establishing of a JV structure and advise on...